The emerging treatment landscape of targeted therapy in non-small-cell lung cancer | Signal Transduction and Targeted Therapy
Lung cancer with MET exon 14 skipping mutation | LCTT
i>MET</i> Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. - Abstract - Europe PMC
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exo | LCTT
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities | Semantic Scholar
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Diagnosis and Discussion -- Case 1068
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer | Oncology
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Cancers | Free Full-Text | Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer | HTML
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Annals of Oncology
FDA approves mobocertinib for EGFR exon 20 insertion+ NSCLC - Lung Cancer Research Foundation
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer | Journal of Hematology & Oncology | Full Text
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy - Cheng - 2021 - MedComm - Wiley Online Library
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Lung cancer with MET exon 14 skipping mutation | LCTT
Advances in Targeted Therapies, Immunotherapy Improve Treatment Options for Patients With Lung Cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation
Timeline for crizotinib development. Abbreviations: ALK1, ALK-positive;... | Download Scientific Diagram
Targeting MET Exon 14 Skipping Mutations in Non-Small Cell Lung Cancer - Cancer Therapy Advisor
Heymach Discusses MET Exon 14 Skipping Mutations in NSCLC
Timeline of key events in the development of METex14 altered NSCLC... | Download Scientific Diagram
